{"disease":{"id":"b-acute-lymphoblastic-leukemia-with-t-9-22-q34-1-q11-2-bcr-abl1","name":"b acute lymphoblastic leukemia with t 9 22 q34 1 q11 2 bcr abl1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01190930","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9350,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05602194","title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04530565","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":348,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01371630","title":"Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00792948","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01424982","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01139970","title":"Veliparib and Temozolomide in Treating Patients With Acute Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01256398","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00720109","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02143414","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07224100","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT07040982","title":"Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02311998","title":"Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04872790","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02484430","title":"Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}